Home > Publications database > Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort. > print

001     147254
005     20240229123022.0
024 7 _ |a 10.1002/pbc.28022
|2 doi
024 7 _ |a pmid:31571386
|2 pmid
024 7 _ |a 0098-1532
|2 ISSN
024 7 _ |a 1096-911X
|2 ISSN
024 7 _ |a 1545-5009
|2 ISSN
024 7 _ |a 1545-5017
|2 ISSN
024 7 _ |a altmetric:67547017
|2 altmetric
037 _ _ |a DKFZ-2019-02377
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Benesch, Martin
|0 0000-0001-7827-4130
|b 0
245 _ _ |a Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort.
260 _ _ |a New York, NY
|c 2020
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1580111218_3899
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jan;67(1):e28022
520 _ _ |a Case reports have portrayed spinal cord atypical teratoid/rhabdoid tumor (spATRT) as an aggressive form of ATRT. We conducted a retrospective European survey to collect data on clinical characteristics, molecular biology, treatment, and outcome of children with intramedullary spATRT.Scrutinizing a French national series and the European Rhabdoid Registry database, we identified 13 patients (median age 32 months; metastatic disease at diagnosis, n = 6). Systemic postoperative chemotherapy was administered to all patients; three received intrathecal therapy and six were irradiated (craniospinal, n = 3; local, n = 3).Median observation time was 8 (range, 1-93) months. Progression-free and overall survival rates at 1 and (2 years) were 35.2% ± 13.9% (26.4% ± 12.9%) and 38.5% ± 13.5% (23.1% ± 11.7%). Four patients (ATRT-SHH, n = 2; ATRT-MYC, n = 1; DNA methylation subgroup not available, n = 1) achieved complete remission (CR); two of them are alive in CR 69 and 72 months from diagnosis. One patient relapsed after CR and is alive with progressive disease (PD) and one died of the disease. Three patients (ATRT-MYC, n = 2; subgroup not available, n = 1) died after 7 to 22 months due to PD after having achieved a partial remission (n = 1) or stabilization (n = 2). Five patients (ATRT-MYC, n = 2; subgroup not available, n = 3) developed early PD and died. One patient (ATRT-MYC) died of intracerebral hemorrhage prior to response evaluation.Long-term survival is achievable in selected patients with spATRT using aggressive multimodality treatment. Larger case series and detailed molecular analyses are needed to understand differences between spATRT and their inracranial counterparts and the group of extradural malignant rhabdoid tumors.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Nemes, Karolina
|0 0000-0003-0270-5875
|b 1
700 1 _ |a Neumayer, Petra
|b 2
700 1 _ |a Hasselblatt, Martin
|b 3
700 1 _ |a Timmermann, Beate
|b 4
700 1 _ |a Bison, Brigitte
|b 5
700 1 _ |a Ebetsberger-Dachs, Georg
|b 6
700 1 _ |a Bourdeaut, Franck
|b 7
700 1 _ |a Dufour, Christelle
|0 0000-0001-5993-8077
|b 8
700 1 _ |a Biassoni, Veronica
|b 9
700 1 _ |a Morales La Madrid, Andrés
|b 10
700 1 _ |a Entz-Werle, Natacha
|b 11
700 1 _ |a Laithier, Véronique
|b 12
700 1 _ |a Quehenberger, Franz
|b 13
700 1 _ |a Weis, Serge
|b 14
700 1 _ |a Sumerauer, David
|b 15
700 1 _ |a Siebert, Reiner
|b 16
700 1 _ |a Bens, Susanne
|b 17
700 1 _ |a Schneppenheim, Reinhard
|b 18
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 19
|u dkfz
700 1 _ |a Modena, Piergiorgio
|0 0000-0002-2339-4300
|b 20
700 1 _ |a Fouyssac, Fanny
|b 21
700 1 _ |a C Frühwald, Michael
|0 0000-0002-8237-1854
|b 22
773 _ _ |a 10.1002/pbc.28022
|0 PERI:(DE-600)2130978-4
|n 1
|p e28022
|t Pediatric blood & cancer
|v 67
|y 2020
|x 1545-5017
909 C O |p VDB
|o oai:inrepo02.dkfz.de:147254
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PEDIATR BLOOD CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21